Last Updated on February 24, 2026 by Rajat Bhati

Cancer-care operator Oncare has raised INR 27 crore in a Series A round led by Sky Impact Capital, with participation from Huddle Ventures, Lotus Herbal Group, Steerx and Tremis Capital. The Gurugram-based startup builds and runs oncology departments inside mid-sized, non-branded hospitals.

Oncare Series A Round: Use of Funds

Oncare plans to use the proceeds to enter Bengaluru and open tertiary-city centres across Uttar Pradesh, Bihar and West Bengal over the next year. “We’ll use this fund to expand into Bangalore and open a few tertiary-city centres,” cofounder Deepak Kumar said, outlining demand in underserved markets. Oncare currently operates four centres across Delhi-NCR.

Positioning itself as a lower-cost alternative to corporate hospitals, the startup said it can price chemotherapy about 40% cheaper—around INR 24,000–25,000 per session versus roughly INR 40,000—while surgeries are typically 30–40% lower. Its model integrates medical, surgical and radiation oncology services within accredited partner hospitals to standardise care at a lower capital outlay.

Traction, Founding and Prior funding

Since its inception, Oncare has engaged with around 30,000 patients, facilitated about 3,000 oncologist consultations and treated roughly 1,000 patients, amounting to over 4,000 procedures. The company was founded in 2023 by Deepak Kumar and Amar Sneh and is headquartered in Gurugram. It previously raised about USD 1 million (~INR 8.3 crore) in a seed round in October 2024, led by Huddle Ventures.

Investor interest in oncology and speciality-care delivery has been rising, with recent transactions and pipeline momentum highlighted in industry coverage. Oncare’s raise adds to that trend even as operators look to balance affordability with unit economics in a competitive, capital-intensive category.

Key Highlights of Oncare Series A Funding

• Round: Series A, INR 27 crore; lead investor Sky Impact Capital
• Participants: Huddle Ventures, Lotus Herbal Group, Steerx, Tremis Capital
• Use of funds: Expansion to Bengaluru; new centres in UP, Bihar, West Bengal
• Footprint: Four centres across Delhi-NCR; Gurugram HQ
• Pricing claim: Chemo ~INR 24,000–25,000 per session vs ~INR 40,000 at large hospitals

Bottomline: Oncare’s capital-light, partner-hospital model is pitched at widening access to oncology while keeping bills lower than corporate peers. Oncare Series A funding of INR 27 crore gives it a runway to test that thesis beyond Delhi-NCR, with execution in Bengaluru and eastern markets set to determine the next leg of growth.

For more details related to IPO GMP, SEBI IPO Approval, REIT, InvIT and Live Subscription stay tuned to IPO Central.